Protagonist Therapeutics Announces Promising Icotrokinra Study Results for Plaque Psoriasis

Protagonist Therapeutics revealed promising findings from their ICONIC-LEAD Phase 3 study of icotrokinra, an investigational oral peptide for treating moderate-to-severe plaque psoriasis in adolescents. Data presented at the 2025 World Congress of Pediatric Dermatology show 84.1% of adolescents achieved clear or almost clear skin by Week 16. By Week 24, 75% achieved completely clear skin, showcasing both efficacy and a favorable safety profile, with fewer adverse events compared to placebo.

The ICONIC-LEAD study is a groundbreaking approach in simultaneous assessment for adults and adolescents. The once-daily oral treatment selectively blocks the IL-23 receptor, representing a significant advancement in non-injectable options for psoriasis sufferers.